Peritoneal cancer treatment with targeted therapy

Targeted therapy, like bevacizumab (Avastin), is an effective treatment for advanced primary peritoneal carcinoma. It blocks the blood vessels that feed the tumor, slowing down or shrinking its growth. Combining bevacizumab with chemotherapy enhances treatment by attacking the cancer from different angles. The decision to use bevacizumab and other targeted therapies is based on the tumor's characteristics and the patient's condition. In addition, close monitoring helps manage potential side effects. The treatment process starts with a comprehensive examination, including medical history, physical exams, and consultations with a specialist. Next, lab tests and imaging scans like ultrasound and CT scans provide a clearer picture of the tumor. Additional tests, such as histopathological specimen re-examination and genetic mutation testing, help confirm the diagnosis and create the treatment plan. Once diagnosed, targeted therapy begins after pre-procedure preparation. Post-procedure care involves monitoring the patient's response and managing side effects. Symptomatic treatment addresses any associated symptoms. Targeted therapy may be used alone or alongside surgery, chemotherapy, or immunotherapy depending on the patient's needs. It offers improved tumor control, prolonged survival rates, and reduced side effects compared to conventional treatments. Personalized and precise, targeted therapy improves prognosis and enhances the patient's life quality.